Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tutkimus haittatapahtumien, sairauden aktiivisuuden muutosten ja suonensisäisen ja ihonalaisen risankitsumabin kulkua potilaiden kehon läpi, joilla on kohtalaisen tai vaikeasti aktiivinen Crohnin tauti (RISE)

torstai 15. lokakuuta 2026 päivittänyt: AbbVie

Vaihe 3, monikeskustutkimus, jossa arvioidaan risankitsumabin farmakokinetiikkaa, tehoa ja turvallisuutta avoimella induktiolla, satunnaistetulla kaksoissokkohuollolla ja pitkäaikaisilla pidennysjaksoilla lapsipotilailla (2–< 18-vuotiaat) Kohtalaisen tai vaikeasti aktiivinen Crohnin tauti

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

110

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • North Holland
      • Amsterdam, North Holland, Alankomaat, 1105 AZ
        • Rekrytointi
        • Amsterdam University Medical Center /ID# 254827
      • Brussels, Belgia, 1020
        • Rekrytointi
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège, Belgia, 4000
        • Rekrytointi
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem, Antwerpen, Belgia, 2650
        • Rekrytointi
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels, Brussels Capital, Belgia, 1200
        • Rekrytointi
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette, Brussels Capital, Belgia, 1090
        • Rekrytointi
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgia, 3000
        • Rekrytointi
        • Universitair Ziekenhuis Leuven /ID# 255098
      • Plovdiv, Bulgaria, 4002
        • Rekrytointi
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia, Bulgaria, 1606
        • Valmis
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna, Bulgaria, 9009
        • Rekrytointi
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
      • Madrid, Espanja, 28009
        • Valmis
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga, Espanja, 29011
        • Rekrytointi
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol, A Coruna, Espanja, 15405
        • Rekrytointi
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
      • Daegu, Etelä -Korea, 41404
        • Rekrytointi
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03080
        • Rekrytointi
        • Seoul National University Hospital /ID# 255318
      • Seoul, Seoul Teugbyeolsi, Etelä -Korea, 06351
        • Rekrytointi
        • Samsung Medical Center /ID# 255284
      • Seoul, Seoul Teugbyeolsi, Etelä -Korea, 03722
        • Rekrytointi
        • Yonsei University Health System - Severance Hospital /ID# 256976
    • Central District
      • Petah Tikva, Central District, Israel, 4920235
        • Rekrytointi
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 91031
        • Rekrytointi
        • Shaare Zedek Medical Center /ID# 254951
      • Messina, Italia, 98125
        • Rekrytointi
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa, Genova, Italia, 16147
        • Rekrytointi
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples, Napoli, Italia, 80131
        • Rekrytointi
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome, Roma, Italia, 00165
        • Rekrytointi
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • Aichi-ken
      • Ōbu, Aichi-ken, Japani, 474-8710
        • Rekrytointi
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi, Chiba, Japani, 277-0871
        • Rekrytointi
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi, Fukuoka, Japani, 830-0011
        • Rekrytointi
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi, Gunma, Japani, 371-8511
        • Rekrytointi
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto, Kumamoto, Japani, 861-8520
        • Rekrytointi
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi, Osaka, Japani, 594-1101
        • Rekrytointi
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi, Saitama, Japani, 330-8777
        • Rekrytointi
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku, Tokyo, Japani, 113-8519
        • Rekrytointi
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi, Tokyo, Japani, 183-8561
        • Rekrytointi
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City, Tokyo, Japani, 157-8535
        • Rekrytointi
        • National Center For Child Health And Development /ID# 268420
    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Rekrytointi
        • Alberta Children's Hospital /ID# 255357
      • Edmonton, Alberta, Kanada, T6G 1C9
        • Rekrytointi
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • Rekrytointi
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • Rekrytointi
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina, 100045
        • Rekrytointi
        • Beijing Children's Hospital /ID# 256081
      • Beijing, Beijing Municipality, Kiina, 100191
        • Rekrytointi
        • Peking University Third Hospital /ID# 255876
        • Ottaa yhteyttä:
          • Site Coordinator
          • Puhelinnumero: +86 010-82266699
    • Guangdong
      • Guangzhou, Guangdong, Kiina, 510620
        • Rekrytointi
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou, Guangdong, Kiina, 510655
        • Rekrytointi
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou, Henan, Kiina, 450018
        • Rekrytointi
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha, Hunan, Kiina, 410007
        • Rekrytointi
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang, Jiangxi, Kiina, 330006
        • Rekrytointi
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang, Liaoning, Kiina, 110022
        • Rekrytointi
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kiina, 200062
        • Rekrytointi
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai, Shanghai Municipality, Kiina, 200065
        • Rekrytointi
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
      • Dorado, Puerto Rico, 00646
        • Rekrytointi
        • Puerto Rico Health Institute /ID# 255071
      • San Juan, Puerto Rico, 00909-1711
        • Rekrytointi
        • Clinical Research Puerto Rico /ID# 266479
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, Puola, 87-100
        • Valmis
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Puola, 04-730
        • Rekrytointi
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
      • Paris, Ranska, 75015
        • Rekrytointi
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Ranska, 37044
        • Rekrytointi
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux, New Aquitaine, Ranska, 33076
        • Rekrytointi
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse, Occitanie, Ranska, 31059
        • Rekrytointi
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron, Rhone, Ranska, 69500
        • Rekrytointi
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
    • Stockholm County
      • Stockholm, Stockholm County, Ruotsi, 118 83
        • Rekrytointi
        • Sodersjukhuset /ID# 255239
      • Stockholm, Stockholm County, Ruotsi, 171 76
        • Rekrytointi
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Ruotsi, 413 46
        • Rekrytointi
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • Ottaa yhteyttä:
          • Site Coordinator
          • Puhelinnumero: +46313435865
    • Bavaria
      • Munich, Bavaria, Saksa, 80337
        • Rekrytointi
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Saksa, 48149
        • Rekrytointi
        • Universitaetsklinikum Muenster /ID# 256762
      • Bern, Sveitsi, 3010
        • Rekrytointi
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich, Canton of Zurich, Sveitsi, 8032
        • Rekrytointi
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337
      • Changhua City, Changhua County, Taiwan, 50006
        • Rekrytointi
        • Changhua Christian Hospital /ID# 256082
      • Taipei, Taiwan, 100
        • Rekrytointi
        • National Taiwan University Hospital /ID# 255679
      • Ankara, Turkki (Türkiye), 06560
        • Rekrytointi
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul, Turkki (Türkiye), 34453
        • Rekrytointi
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul, Turkki (Türkiye), 34899
        • Rekrytointi
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli, Turkki (Türkiye), 41380
        • Rekrytointi
        • Kocaeli University Med Faculty /ID# 256922
    • Praha 17
      • Prague, Praha 17, Tšekki, 128 00
        • Valmis
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague, Praha 5, Tšekki, 150 06
        • Valmis
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Birmingham, Yhdistynyt kuningaskunta, B4 6NH
        • Rekrytointi
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield, England, Yhdistynyt kuningaskunta, S10 2TH
        • Rekrytointi
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • Ottaa yhteyttä:
          • Site Coordinator
          • Puhelinnumero: +44 114 273 0522
    • Greater London
      • London, Greater London, Yhdistynyt kuningaskunta, E1 2ES
        • Rekrytointi
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
    • Arizona
      • Phoenix, Arizona, Yhdysvallat, 85016-7710
        • Rekrytointi
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock, Arkansas, Yhdysvallat, 72202
        • Valmis
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland, California, Yhdysvallat, 94609
        • Rekrytointi
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora, Colorado, Yhdysvallat, 80045
        • Rekrytointi
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando, Florida, Yhdysvallat, 32806-1141
        • Rekrytointi
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis, Indiana, Yhdysvallat, 46202
        • Rekrytointi
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham, Massachusetts, Yhdysvallat, 02451
        • Rekrytointi
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis, Minnesota, Yhdysvallat, 55413-2195
        • Rekrytointi
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown, New Jersey, Yhdysvallat, 07960
        • Rekrytointi
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York, New York, Yhdysvallat, 10029
        • Rekrytointi
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland, Ohio, Yhdysvallat, 44195
        • Rekrytointi
        • Cleveland Clinic - Cleveland /ID# 256453
        • Ottaa yhteyttä:
          • Site Coordinator
          • Puhelinnumero: 216-636-2007

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

2 vuotta - 17 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Peräkkäinen tehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI
Kokeellinen: Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Muut nimet:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Muut nimet:
  • ABBV-066
  • SKYRIZI

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Aikaikkuna: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Aikaikkuna: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Aikaikkuna: Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Aikaikkuna: Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Aikaikkuna: Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Aikaikkuna: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Aikaikkuna: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Aikaikkuna: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Aikaikkuna: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Aikaikkuna: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Aikaikkuna: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Aikaikkuna: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Aikaikkuna: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Aikaikkuna: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Aikaikkuna: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Aikaikkuna: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Aikaikkuna: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: ABBVIE INC., AbbVie

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 11. joulukuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 1. huhtikuuta 2029

Opintojen valmistuminen (Arvioitu)

Sunnuntai 1. huhtikuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 10. elokuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 10. elokuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 16. elokuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 20. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 15. lokakuuta 2026

Viimeksi vahvistettu

Torstai 1. lokakuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • M16-194
  • 2022-502050-14-00 (Muu tunniste: EU CT)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-jaon aikakehys

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD-jaon käyttöoikeuskriteerit

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Yhdysvalloissa valmistettu ja sieltä viety tuote

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa